Recent Updates
Recently added Catalysts
WHWK Positive Sentiment

Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London

Tuesday, November 11, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Whitehawk Therapeutics, an oncology therapeutics company, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. CEO Dave Lennon will discuss the company's innovative antibody drug conjugate (ADC) cancer treatments. A live webcast will be available for those unable to attend the event.
Price reaction · baseline $2.18 (2025-11-10 close) · hit pre-market · clean, no other WHWK news in the window
day 0 close · peak
+2.3%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Whitehawk Therapeutics is advancing cancer treatment technologies.
  • The company is presenting at a significant healthcare conference.
  • Their ADC portfolio aims to improve outcomes for difficult-to-treat cancers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~38 mo
Minimal dilution risk
Lead asset
HWK-016, MUCIN-16-targeted ADC
Phase 1 · PROC

Full Press Release Details

MORRISTOWN, N.J.,Nov. 11, 2025/PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT.
A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IRwebsiteand will be available for replay for approximately 30 days following the event.

About Whitehawk TherapeuticsWhitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available atwww.whitehawktx.comand connect with us on LinkedIn.

Contact:[email protected]

Frequently Asked Questions

When will Whitehawk Therapeutics present?

Whitehawk Therapeutics will present on November 18, 2025.

Who is presenting for Whitehawk Therapeutics?

Dave Lennon, PhD, President and CEO, will present.

How can I access the presentation?

The presentation will be available via a live webcast on their IR website.

What is the focus of Whitehawk Therapeutics?

The company focuses on advanced oncology therapeutics and ADC cancer treatments.

ShareAdd on Google
Tags: WHWK Viatris Investor Conferences Healthcare Whitehawk Therapeutics oncology ADC cancer treatment Jefferies Conference
Last updated: Nov 11, 2025

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London

Biotech snapshot

Cash runway
$190M liquidity · $5M/mo burn
~38 mo
Minimal dilution risk
Lead asset
HWK-016, MUCIN-16-targeted ADCPhase 1
PROC →